To assess the relevance of YKL-40 as a serological biomarker in the ASC setting, we first quantified its serological levels in the ASC cohort and evaluated the association with patients’ clinicopathological features. This evidence concerns the gene CHI3L1 and Tako-tsubo cardiomyopathy.